Literature DB >> 21736885

Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats.

Elena Chartoff1, Allison Sawyer, Anna Rachlin, Dave Potter, Andrea Pliakas, William A Carlezon.   

Abstract

Drug dependence is characterized by dysregulation of brain reward systems and increased sensitivity to stress. Chronic exposure to drugs of abuse is associated with increased expression of the neuropeptide dynorphin, the endogenous ligand for kappa opioid receptors (KORs). Activation of KORs causes depressive- and aversive-like responses in rodents, raising the possibility that drug-induced upregulation of dynorphin plays a role independence-associated negative states. Here we used "binge" exposure to cocaine (3 daily intraperitoneal injections of 15 mg/kg for 14 days) to examine the development of dependence-like behavior in the intracranial self-stimulation (ICSS) test and the forced swim test (FST). When rats were tested 1 h before their first scheduled injection of each day-a period of drug withdrawal corresponding to 20 h after their last injection on the previous day-there were exposure-dependent increases in ICSS thresholds (a putative indicator of anhedonia) and decreases in latencies to immobility in the FST (a putative indicator of behavioral despair). Administration of the long-lasting KOR antagonist norBNI (20 μg, intracerebroventricular) before the beginning of the binge regimen attenuated the development of cocaine withdrawal-induced anhedonia in the ICSS test. In contrast, administration of norBNI in the midst of the binge regimen had no effect on expression of cocaine withdrawal-induced anhedonia in the ICSS test, although it did attenuate despair-like behavior in the FST. These data suggest that blockade of KORs before exposure to a stressor (in this case, cocaine withdrawal or forced swimming) can attenuate the development of stress-induced behavioral adaptations. This article is part of a Special Issue entitled 'Anxiety and Depression'.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21736885      PMCID: PMC3195851          DOI: 10.1016/j.neuropharm.2011.06.014

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  61 in total

1.  Repeated exposure to the κ-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity.

Authors:  David N Potter; Diane Damez-Werno; William A Carlezon; Bruce M Cohen; Elena H Chartoff
Journal:  Biol Psychiatry       Date:  2011-07-14       Impact factor: 13.382

Review 2.  The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse.

Authors:  Sunmee Wee; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2010-03-30       Impact factor: 4.530

3.  Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect.

Authors:  Samuel S Newton; Johannes Thome; Tanya L Wallace; Yukihikko Shirayama; Lee Schlesinger; Norio Sakai; Jingshan Chen; Rachael Neve; Eric J Nestler; Ronald S Duman
Journal:  J Neurosci       Date:  2002-12-15       Impact factor: 6.167

4.  Differential gene expression in the rat caudate putamen after "binge" cocaine administration: advantage of triplicate microarray analysis.

Authors:  Vadim Yuferov; Thomas Kroslak; K Steven Laforge; Yan Zhou; Ann Ho; Mary Jeanne Kreek
Journal:  Synapse       Date:  2003-06-15       Impact factor: 2.562

5.  Environmental-enrichment-related variations in behavioral, biochemical, and physiologic responses of Sprague-Dawley and Long Evans rats.

Authors:  Anne T M Konkle; Amanda C Kentner; Stephanie L Baker; Angela Stewart; Catherine Bielajew
Journal:  J Am Assoc Lab Anim Sci       Date:  2010-07       Impact factor: 1.232

6.  Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats.

Authors:  Stephen D Mague; Andrea M Pliakas; Mark S Todtenkopf; Hilarie C Tomasiewicz; Yan Zhang; William C Stevens; Robert M Jones; Philip S Portoghese; William A Carlezon
Journal:  J Pharmacol Exp Ther       Date:  2003-04       Impact factor: 4.030

7.  Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses.

Authors:  Jay P McLaughlin; Monica Marton-Popovici; Charles Chavkin
Journal:  J Neurosci       Date:  2003-07-02       Impact factor: 6.167

Review 8.  A review of the properties of spiradoline: a potent and selective kappa-opioid receptor agonist.

Authors:  M-L G Wadenberg
Journal:  CNS Drug Rev       Date:  2003

9.  Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats.

Authors:  Mark S Todtenkopf; Jacqueline F Marcus; Philip S Portoghese; William A Carlezon
Journal:  Psychopharmacology (Berl)       Date:  2004-01-16       Impact factor: 4.530

Review 10.  A 'crash' course on psychostimulant withdrawal as a model of depression.

Authors:  Alasdair M Barr; Athina Markou; Anthony G Phillips
Journal:  Trends Pharmacol Sci       Date:  2002-10       Impact factor: 14.819

View more
  74 in total

1.  Effects of withdrawal from chronic escalating-dose binge cocaine on conditioned place preference to cocaine and striatal preproenkephalin mRNA in C57BL/6J mice.

Authors:  Yong Zhang; Stefan D Schlussman; Eduardo R Butelman; Ann Ho; Mary Jeanne Kreek
Journal:  Neuropharmacology       Date:  2012-04-04       Impact factor: 5.250

Review 2.  Motivational Processes Underlying Substance Abuse Disorder.

Authors:  Paul J Meyer; Christopher P King; Carrie R Ferrario
Journal:  Curr Top Behav Neurosci       Date:  2016

3.  κ-Opioid receptors within the nucleus accumbens shell mediate pair bond maintenance.

Authors:  Shanna L Resendez; Morgan Kuhnmuench; Tarin Krzywosinski; Brandon J Aragona
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

Review 4.  Pain and suicidality: insights from reward and addiction neuroscience.

Authors:  Igor Elman; David Borsook; Nora D Volkow
Journal:  Prog Neurobiol       Date:  2013-07-01       Impact factor: 11.685

Review 5.  The development and maintenance of drug addiction.

Authors:  Roy A Wise; George F Koob
Journal:  Neuropsychopharmacology       Date:  2013-10-11       Impact factor: 7.853

6.  The Dark Side of Addiction: The Horsley Gantt to Joseph Brady Connection.

Authors:  George F Koob
Journal:  J Nerv Ment Dis       Date:  2017-04       Impact factor: 2.254

Review 7.  Substance use modulates stress reactivity: Behavioral and physiological outcomes.

Authors:  Anne Q Fosnocht; Lisa A Briand
Journal:  Physiol Behav       Date:  2016-02-19

Review 8.  Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.

Authors:  William A Carlezon; Andrew D Krystal
Journal:  Depress Anxiety       Date:  2016-10       Impact factor: 6.505

9.  κ Opioid receptors in the nucleus accumbens shell mediate escalation of methamphetamine intake.

Authors:  Timothy W Whitfield; Joel E Schlosburg; Sunmee Wee; Adam Gould; Olivier George; Yanabel Grant; Eva R Zamora-Martinez; Scott Edwards; Elena Crawford; Leandro F Vendruscolo; George F Koob
Journal:  J Neurosci       Date:  2015-03-11       Impact factor: 6.167

10.  Sex differences in sensitivity to the depressive-like effects of the kappa opioid receptor agonist U-50488 in rats.

Authors:  Shayla E Russell; Anna B Rachlin; Karen L Smith; John Muschamp; Loren Berry; Zhiyang Zhao; Elena H Chartoff
Journal:  Biol Psychiatry       Date:  2013-10-03       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.